Literature DB >> 27832710

Radiation exposure in patients with inflammatory bowel disease and irritable bowel syndrome in the years 2001-2011.

Hanna Englund1, Katarina Lidén K1, Torbjörn Lind2, Torbjörn Sundström3, Pontus Karling1.   

Abstract

OBJECTIVES: To compare cumulative ionizing radiation in patients with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) for the years 2001-2011. To study how radiation exposure change over time in patients with newly diagnosed IBD and factors associated with radiation exposure.
MATERIAL AND METHODS: All radiological investigations performed between 1 January 2001 and 31 December 2011 were retrospectively recorded in patients with Crohn's disease (CD) (n = 103), ulcerative colitis (UC) (n = 304) and IBS (n = 149). Analyses were done with Mann-Whitney and Chi-Square test.
RESULTS: The median total cumulative radiation exposure in mSv for CD (20.0, inter quartile range (IQR) 34.8), UC (7.01, IQR 23.8), IBS (2.71, IQR 9.15) and the proportion of patients who had been exposed for more than 50 mSv during the study period (CD 19%, UC 11%, IBS 3%) were significantly higher in the patients with CD compared to patients with UC (p < .001) and IBS (p < .001), respectively. In turn, patients with UC had significantly higher doses than patients with IBS (p = .005). Risk factors for radiation exposure were female gender (CD), early onset (UC), ileocolonic location (CD), previous surgery (CD and UC), depression (IBS) and widespread pain (IBS). In newly diagnosed CD, there was a significant decline in median cumulative radiation dose in mSv (17.2 vs. 12.0; p = .048) during the study period.
CONCLUSIONS: Patients with CD are at greatest risk for high cumulative radiation exposure, but there is a decline in exposure during the late 2000s. Non-colectomized patients with UC and patients with IBS have a relatively low risk of cumulative radiation exposure.

Entities:  

Keywords:  IBD-clinical; colonic disorders; computer-technology; functional disorders; small-intestinal disorders

Mesh:

Year:  2016        PMID: 27832710     DOI: 10.1080/00365521.2016.1252945

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  6 in total

1.  Depression Is Associated With More Aggressive Inflammatory Bowel Disease.

Authors:  Bharati Kochar; Edward L Barnes; Millie D Long; Kelly C Cushing; Joseph Galanko; Christopher F Martin; Laura E Raffals; Robert S Sandler
Journal:  Am J Gastroenterol       Date:  2017-11-14       Impact factor: 10.864

2.  Imaging of the small intestine in Crohn's disease: Joint position statement of the Indian Society of Gastroenterology and Indian Radiological and Imaging Association.

Authors:  Saurabh Kedia; Raju Sharma; Govind K Makharia; Vineet Ahuja; Devendra Desai; Devasenathipathy Kandasamy; Anu Eapen; Karthik Ganesan; Uday C Ghoshal; Naveen Kalra; D Karthikeyan; Kumble Seetharama Madhusudhan; Mathew Philip; Amarender Singh Puri; Sunil Puri; Saroj K Sinha; Rupa Banerjee; Shobna Bhatia; Naresh Bhat; Sunil Dadhich; G K Dhali; B D Goswami; S K Issar; V Jayanthi; S P Misra; Sandeep Nijhawan; Pankaj Puri; Avik Sarkar; S P Singh; Anshu Srivastava; Philip Abraham; B S Ramakrishna
Journal:  Indian J Gastroenterol       Date:  2018-01-06

3.  Are We Overradiating Patients with Irritable Bowel Syndrome?

Authors:  Yousaf B Hadi; Adnan Aman Khan; Syeda F Z Naqvi; Salman Khan; Jesse Thompson; Justin T Kupec
Journal:  Inflamm Intest Dis       Date:  2020-12-09

4.  Multinational data on cumulative radiation exposure of patients from recurrent radiological procedures: call for action.

Authors:  Marco Brambilla; Jenia Vassileva; Agnieszka Kuchcinska; Madan M Rehani
Journal:  Eur Radiol       Date:  2019-12-02       Impact factor: 5.315

5.  Cumulative Effective Dose from Medical Imaging in Inflammatory Bowel Disease.

Authors:  Agata Łukawska; Dominika Ślósarz; Aneta Zimoch; Karol Serafin; Elżbieta Poniewierka; Radosław Kempiński
Journal:  Diagnostics (Basel)       Date:  2021-12-18

6.  Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease.

Authors:  Jonathan W Lischalk; Seth Blacksburg; Christopher Mendez; Michael Repka; Astrid Sanchez; Todd Carpenter; Matthew Witten; Jules E Garbus; Andrew Evans; Sean P Collins; Aaron Katz; Jonathan Haas
Journal:  Radiat Oncol       Date:  2021-07-09       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.